Acute myeloid leukemia is a clonal neoplasm derived from myeloid progenitor cells with a
varying outcome. The initial goal of treatment is the achievement of complete remission …

In recent years, allogeneic hematopoietic stem cell transplantation (allo-HSCT) has become
increasingly common in patients with acute myelogenous leukemia (AML) due to improved …

Haploidentical hematopoietic stem cell transplants (HSCTs) are increasingly used, but it is
unknown whether they have a stronger graft-versus-leukemia (GVL) effect. We analyzed 10 …

Although allogeneic hematopoietic stem cell transplantation from an HLA-matched sibling
donor (MSD) is a potentially curative post-remission treatment for adults with acute myeloid …

Background Optimal post-remission strategy for patients with acute myeloid leukemia (AML)
is matter of intense debate. Recent reports have shown stronger anti-leukemic activity but …

Nonrelapse mortality (NRM) is the first cause of treatment failure after unrelated cord blood
transplantation (UCBT) following myeloablative conditioning (MAC). In the last decade …

Allogeneic hematopoietic cell transplantation (alloHCT) is considered the most potent
postremission antileukemic therapy in adults with acute leukemia. We analyzed 172 …

Background/Aim: Evaluations of efficacy of treatment modality in analyses on patients with
acute myeloid leukemia (AML) often combine chemotherapy and stem cell transplantation …

Background/Aim: Minimal residual disease (MRD) in patients with acute myeloid leukemia
(AML) before allogeneic hematopoietic stem cell transplantation (alloHSCT) can influence …

Human recombinant granulocyte colony–stimulating factor (G-CSF), filgrastim (Neupogen;
Amgen, Thousand Oaks, CA, USA), has been widely used for the mobilization of CD34+ …